MY INTELLIGENT MACHINES INC.
SECURES $5 MILLION IN SEED FINANCING
TO SUPPORT INTERNATIONAL SALES
AND GROWING CAPABILITIES
MONTREAL, CANADA – April 15, 2021 – My Intelligent Machines Inc. (“MIMs”), a leader in artificial intelligence and systems biology, today announced that it has completed an equity financing of $5 million. Capital raised will support the company’s expansion into Canadian, European and U.S. markets, as well as hiring talent to deliver key projects to top pharmaceutical companies and hospitals.
The financing was led by MEDTEQ+ and StandUp Ventures, with participation from Desjardins Capital, Anges Québec, Anges Québec Capital and Real Ventures.
“Our AI-based systems biology approach injects precision medicine very early into the drug discovery process. We can provide a better understanding of patient heterogeneity with respect to both disease and response to treatment. Our platform enables the identification of targets for drugs with increased efficacy, prioritization of indications at pre-clinical stages and reduction of clinical trial failure rate,” said Sarah Jenna, Ph.D., co-founder and CEO of My Intelligent Machines. “Our suite represents a real paradigm shift in how discovery and pre-clinical studies are conducted, and it could save up to $500 million in the development of a given drug, considering a lower drug development failure rate, faster market approval and fewer and less exhaustive clinical trials. In this context, we are privileged to count on a solid base of committed investors who acknowledge the potential of our technology and the relevance of our business model with their involvement in our capital expansion,” completed Dr. Jenna.
“MIMs team is currently firing on all cylinders, being especially well-positioned to serve a wide market with a product that addresses a huge unmet need. Now that their anchor and internationally-respected customer’s product has been delivered, we already witness a growing appetite from many players in Pharma for MIMs’ AI-based solution,” said Robert Ritlop, Director of Investments at MEDTEQ+.
“Identifying subsets within a population is critical for the enablement of personalized medicine, but to do this effectively and at scale requires advanced artificial intelligence techniques - something life scientists often don't have expertise in. MIMs removes this barrier to entry, paving the way for better and faster drug development,” stated Michelle McBane, Managing Director at StandUp Ventures.
Proceeds of this round will allow MIMs to triple in size and to fulfill contracts worth tens of million dollars over a 24-month period. With capabilities steadily ramping up, MIMs will be in a favourable position to scale up its operations and focus on high-value opportunities in oncology, immunology and COVID-19, in Canada, the United States and Europe.
About MIMs’ SaaS solutions
MIMs markets augmented intelligence systems packaged in a software-as-a-service (SaaS) solution, dedicated to life scientists working in pharma and biotech companies. Whereas conventional AI solutions typically operate as a ‘black box’, My Intelligent Machines software solutions work in synergy with life scientists, making accurate human biology simulations possible far sooner than the significant costs and risks currently incurred in late-stage clinical development. MIMs’ software allows for early-stage patient stratification, endotype characterization, as well as target and biomarker discovery with a precision, never reached before.
Montreal-based My Intelligent Machines (MIMs) is a leader in artificial intelligence and systems biology. MIMs provides Biopharma and Agtech companies of all sizes with easy-to-implement and interactive augmented intelligence systems, allowing for accurate biological simulations at early drug development stage, to assist life scientists in the development of precisely targeted and personalized therapies. In late 2020, MIMs received the Red Herring’s Top 100 North America Award, one of the most prestigious prizes granted each year to the most promising private tech companies.
MEDIA & INVESTOR INQUIRIES
Annalie Sabri Ledesma